Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. (18th January 2021)

• Record Type: Journal Article
• Authors: Gan, Chun Loo; Dudani, Shaan; Wells, J. Connor; Donskov, Frede; Pal, Sumanta K.; Dizman, Nazli; Rathi, Nityam; Beuselinck, Benoit; Yan, Flora; Lalani, Aly‐Khan A.; Hansen, Aaron; Szabados, Bernadett; de Velasco, Guillermo; Tran, Ben; Lee, Jae Lyun; Vaishampayan, Ulka N.; Bjarnason, Georg A.; Subasri, Mathushan; Choueiri, Toni K.; Heng, Daniel Y. C.
• Is Part Of: Cancer medicine. Volume 10:Number 4(2021)
• Page Start: 1212
• Page End: 1221
• Publication Date: 2021-01-18
• Subjects: cabozantinib -- first line -- fourth line -- IMDC -- real‐world -- renal‐cell carcinoma -- response rates -- second line -- survival -- third line; 616.994005
• DOI: 10.1002/cam4.3717
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: Background: Cabozantinib is approved for metastatic renal cell carcinoma (mRCC) based on the METEOR and CABOSUN trials. However, real‐world effectiveness and dosing patterns of cabozantinib are not well characterized. Methods: Patients with mRCC treated with cabozantinib between 2011 and 2019 were identified and stratified using the International mRCC Database Consortium (IMDC) risk groups. First‐ (1L), second‐ (2L), third‐ (3L), and fourth‐line (4L) overall response rate (ORR), time to treatment failure (TTF), and overall survival (OS) were analyzed. Dose reduction rates and their association with TTF and OS were determined. Results: A total of 413 patients were identified. The ORRs across 1L to 4L were 32%, 26%, 25%, and 29%, respectively, and the median TTF rates were 8.3, 7.3, 7.0, and 8.0 months, respectively. The median OS (mOS) rates in 1L to 4L were 30.7, 17.8, 12.6, and 14.9 months, respectively. For patients treated with 1L PD(L)1 combination agent ( n = 31), 2L cabozantinib had ORR of 22%, median TTF of 5.4 months, and mOS of 17.4 months. About 50% (129/258) of patients required dose reductions. The TTF and mOS were significantly longer for patients who required dose reduction vs. patients who did not, with an adjusted hazard ratio of 0.37 (95% CI 0.202–0.672, p < 0.01) and 0.46 (95% CI 0.215–0.980, p = 0.04), respectively. Limitations include the retrospective study design and the lack of central radiology review. Conclusion: The ORR and TTF of cabozantinib were maintained from the 1L to 4L settings. Dose reductions due to toxicity were associated with improved TTF and OS. Cabozantinib has clinical activity after 1L Immuno‐oncology combination agents. Abstract : Cabozantinib demonstrates activity for use in real‐world patients with metastatic renal cell carcinoma across the first‐ to fourth‐line treatment settings.